Get started
Author

Ewelina Kulikowski

Observed names: E Kulikowski, E. Kulikowski, EWELINA KULIKOWSKI, Kulikowski, E, Kulikowski, Ewelina
Observed institutions: University of Calgary, University of California, Irvine, VA Palo Alto Health Care System, Amsterdam UMC Location University of Amsterdam, AraVasc (United States), CGH Medical Center, Resverlogix (Canada), Bolder Biotechnology, Inc., Imperial College London
ORCID: 0000-0001-5428-3008
Observed ORCID: 0000-0001-5428-3008
OpenAlex ID: A5002753725
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection
2021 · Richard J. Mills, Sean J. Humphrey, et al. · Cell · 227
PDF
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes
2020 · Kausik K. Ray, Stephen J. Nicholls, et al. · JAMA · 172
PDF
Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension
2019 · Diederik E. Van der Feen, Kondababu Kurakula, et al. · American Journal of Respiratory and Critical Care Medicine · 157
PDF
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
2019 · Laura M. Tsujikawa, Li Fu, et al. · Clinical Epigenetics · 128
PDF
Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease
2017 · Stephen J. Nicholls, Kausik K. Ray, et al. · American Journal of Cardiovascular Drugs · 123
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease
2016 · Dean Gilham, Sylwia Wasiak, et al. · Atherosclerosis · 117
Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
2020 · Ewelina Kulikowski, Brooke D. Rakai, et al. · Medicinal Research Reviews · 109
PDF
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study
2021 · the BETonMACE Investigators, Stephen J. Nicholls, et al. · Cardiovascular Diabetology · 86
PDF
Apabetalone downregulates factors and pathways associated with vascular calcification
2018 · Dean Gilham, Laura M. Tsujikawa, et al. · Atherosclerosis · 65
PDF
Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome
2021 · Kamyar Kalantar-Zadeh, Gregory G. Schwartz, et al. · Clinical Journal of the American Society of Nephrology · 64
PDF
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease
2017 · Ravi Jahagirdar, Sarah Attwell, et al. · Molecular Pharmacology · 61
PDF
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
2019 · Kausik K. Ray, Stephen J. Nicholls, et al. · American Heart Journal · 56
Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)
2017 · Sylwia Wasiak, Dean Gilham, et al. · Journal of Cardiovascular Translational Research · 51
PDF
Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease
2018 · Ewelina Kulikowski, Christopher Halliday, et al. · Kidney & Blood Pressure Research · 46
BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes
2020 · Sylwia Wasiak, Kim E. Dzobo, et al. · Clinical Epigenetics · 45
PDF
Benefit of Apabetalone on Plasma Proteins in Renal Disease
2017 · Sylwia Wasiak, Laura M. Tsujikawa, et al. · Kidney International Reports · 42
PDF
The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial
2018 · Daisuke Shishikura, Yu Kataoka, et al. · American Journal of Cardiovascular Drugs · 39
Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease
2019 · Mathias Haarhaus, Kausik K. Ray, et al. · Atherosclerosis · 38
PDF
Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease
2019 · Mathias Haarhaus, Dean Gilham, et al. · Current Opinion in Nephrology & Hypertension · 34
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
2021 · Dean Gilham, Audrey L Smith, et al. · Biomedicines · 32
PDF
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
2021 · Gregory G. Schwartz, Stephen J. Nicholls, et al. · Cardiovascular Diabetology · 28
PDF
Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells
2022 · Sylwia Wasiak, Laura M. Tsujikawa, et al. · Atherosclerosis · 26
Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial
2021 · Jeffrey Cummings, Gregory G. Schwartz, et al. · Journal of Alzheimer s Disease · 26
Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease
2022 · Peter P. Toth, Gregory G. Schwartz, et al. · American Journal of Preventive Cardiology · 18
PDF
Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes
2016 · Sylwia Wasiak, Dean Gilham, et al. · Data in Brief · 17
PDF
Works count: 123
Citation count: 1,907
H-index: 23
I10-index: 29
Year
Topic
Type